stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Revenue growth
Natera, Inc.'s revenue growth over the twelve months to 30 September 2026 was 37.4%, up 1.5 percentage points from fiscal 2025 (35.9%). Over the past ten years it has ranged from −1.36% (fiscal 2017) to 60.0% (fiscal 2021); the current reading is higher than 82% of that period. That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 35.9% | (20.85) |
| FY2024 | 56.8% | 24.76 |
| FY2023 | 32.0% | 0.86 |
| FY2022 | 31.1% | (28.84) |
| FY2021 | 60.0% | 30.64 |
| FY2020 | 29.3% | 11.99 |
| FY2019 | 17.3% | (5.57) |
| FY2018 | 22.9% | 24.27 |
| FY2017 | −1.36% | (13.00) |
| FY2016 | 11.6% | (7.86) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 34.1% | (3.63) |
| Jun 2026 | 37.7% | (1.11) |
| Mar 2026 | 38.8% | (0.97) |
| Dec 2025 | 39.8% | 5.13 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| WAT Waters Corporation compare | 80.7% |
| NTRA Natera, Inc. | 37.4% |
| IDXX IDEXX Laboratories, Inc. compare | 11.9% |
| DGX Quest Diagnostics Incorporated compare | 9.13% |
| IQV IQVIA Holdings Inc. compare | 8.85% |
| A Agilent Technologies, Inc. compare | 8.60% |
| MTD Mettler-Toledo International, Inc. compare | 6.91% |
| LH Labcorp Holdings Inc. compare | 6.02% |
| ILMN Illumina, Inc. compare | 5.83% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement